157 related articles for article (PubMed ID: 31281432)
1. Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse.
Murray NP; Aedo S; Villalon R; López MA; Minzer S; Muñoz L; Orrego S; Contreras L; Arzeno L; Guzman E
Ecancermedicalscience; 2019; 13():935. PubMed ID: 31281432
[TBL] [Abstract][Full Text] [Related]
2. Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone.
Murray NP; Aedo S; Villalon R; Albarran V; Orrego S; Guzman E
Ecancermedicalscience; 2020; 14():1119. PubMed ID: 33209110
[TBL] [Abstract][Full Text] [Related]
3. Immune Dysfunction as Measured by the Systemic Immune-Inflammation Index is Associated with the Sub-Type of Minimal Residual Disease and Outcome in Stage II Colon Cancer Treated with Surgery alone.
Murray NP; Villalon R; Orrego S; Guzman E
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2391-2397. PubMed ID: 34452551
[TBL] [Abstract][Full Text] [Related]
4. Subtypes of minimal residual disease, association with Gleason score, risk and time to biochemical failure in pT2 prostate cancer treated with radical prostatectomy.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
Ecancermedicalscience; 2019; 13():934. PubMed ID: 31281431
[TBL] [Abstract][Full Text] [Related]
5. The CAPRA score versus sub-types of minimal residual disease to predict biochemical failure after external beam radiotherapy.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
Ecancermedicalscience; 2020; 14():1042. PubMed ID: 32565895
[TBL] [Abstract][Full Text] [Related]
6. Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome.
Murray NP; Villalon R; Hartmann D; Rodriguez MP; Aedo S
Colorectal Dis; 2021 Nov; 23(11):2879-2893. PubMed ID: 34473913
[TBL] [Abstract][Full Text] [Related]
7. The association of the neutrophil-lymphocyte ratio with the presence of minimal residual disease and outcome in patients with Stage II colon cancer treated with surgery alone.
Murray NP; Villalon R; Orrego S; Guzman E
Colorectal Dis; 2021 Apr; 23(4):805-813. PubMed ID: 33169474
[TBL] [Abstract][Full Text] [Related]
8. Improvement in the Neutrophil-Lymphocyte Ratio after Combined Fluorouracil, Leucovorina and Oxaliplatino based (FOLFOX) Chemotherapy for Stage III Colon Cancer is Associated with Improved Minimal Residual Disease and Outcome.
Murray NP; Villalon R; Hartmann D; Rodriguez PM; Aedo S
Asian Pac J Cancer Prev; 2022 Feb; 23(2):591-599. PubMed ID: 35225472
[TBL] [Abstract][Full Text] [Related]
9. [Circulating prostate cells and bone marrow micro-metastasis and not treatment modality determine the risk and time to biochemical failure in low risk prostate cancer.].
Murray NP; Aedo S; Fuentealba C; Salazar A; Reyes E; Lopez MA; Minzer S
Arch Esp Urol; 2019 Dec; 72(10):1000-1009. PubMed ID: 31823848
[TBL] [Abstract][Full Text] [Related]
10. [Circulating prostate cells and bone marrow micrometastasis are determinant in risk and time to biochemical progression in localized prostate cancer.].
Murray NP; Aedo S; Fuentealba C; Reyes E; Minzer S; Salazar A
Arch Esp Urol; 2019 Jun; 72(5):471-482. PubMed ID: 31223125
[TBL] [Abstract][Full Text] [Related]
11. Minimal Residual Disease Defines the Risk and Time to Biochemical Failure in Patients with Pt2 and Pt3a Prostate Cancer Treated With Radical Prostatectomy: An Observational Prospective Study.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Lopez MA; Minzer S; Orrego S; Guzman E
Urol J; 2020 May; 17(3):262-270. PubMed ID: 31912475
[TBL] [Abstract][Full Text] [Related]
12. The Possible Role of Matrix Metalloprotienase-2 in the Relapse in Patients with Stage II Colon Cancer Treated by Curative Surgery.
Murray NP; Villalon R; Aedo S; Hartmann D; Rodriguez MP
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3373-3379. PubMed ID: 37898840
[TBL] [Abstract][Full Text] [Related]
13. The CAPRA-S score versus subtypes of minimal residual disease to predict biochemical failure after radical prostatectomy.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
Ecancermedicalscience; 2020; 14():1063. PubMed ID: 32728379
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of laparoscopic resection of colorectal carcinoma from the viewpoint of molecular biology.
Skrovina M; Duda M; Srovnal J; Bartos J; Radova L; Hajduch M; Soumarova R
Wideochir Inne Tech Maloinwazyjne; 2012 Mar; 7(1):19-26. PubMed ID: 23255996
[TBL] [Abstract][Full Text] [Related]
15. Minimum Residual Disease in Patients Post Radical Prostatectomy for Prostate Cancer: Theoretical Considerations, Clinical Implications and Treatment Outcome.
Murray NP; Aedo S; Fuentealba C; Reyes E; Salazar A
Asian Pac J Cancer Prev; 2018 Jan; 19(1):229-236. PubMed ID: 29374406
[TBL] [Abstract][Full Text] [Related]
16. The Epstein criteria predict for organ-confined prostate cancer but not for minimal residual disease and outcome after radical prostatectomy.
Murray NP; Fuentealba C; Reyes E; Salazar A; Guzman E; Orrego S
Turk J Urol; 2020 Sep; 46(5):360-366. PubMed ID: 32707032
[TBL] [Abstract][Full Text] [Related]
17. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
[TBL] [Abstract][Full Text] [Related]
18. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
Zhou J; Dong F; Cui F; Xu R; Tang X
Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
[TBL] [Abstract][Full Text] [Related]
19. Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse.
Saloustros E; Perraki M; Apostolaki S; Kallergi G; Xyrafas A; Kalbakis K; Agelaki S; Kalykaki A; Georgoulias V; Mavroudis D
Breast Cancer Res; 2011 Jun; 13(3):R60. PubMed ID: 21663668
[TBL] [Abstract][Full Text] [Related]
20. Monitoring with circulating tumor cells in the perioperative setting of patients with surgically treated stages I-IIIA NSCLC.
Garitaonaindia Y; Aguado-Noya R; Garcia-Grande A; Cordoba M; Coronado Albi MJ; Campo Cañaveral JL; Calvo V; Clemente MB; Álvarez R; Peñas M; Chara L; Royuela A; Provencio M
Transl Lung Cancer Res; 2023 Jul; 12(7):1414-1424. PubMed ID: 37577300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
